UBM Tech makes its biggest move yet towards reinventing technology media with the announcement of a new community-driven InformationWeek. Combining the brand’s world renowned content, over 200 new expert contributors, fresh content-sharing tools, and a proven, editorially-facilitated engagement platform, the iconic 34-year old media brand is unlocking the ability for its community members – senior IT professionals – to digitally connect around the most pressing market issues they face. Users will be able to freely share ideas, gather peer feedback, and ultimately help shape the future of the technology market. Start engaging at InformationWeek.com.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/64283-informationweek
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
Barrister, peer and Vice-President of the Patients Association Baroness Helena Kennedy has joined a panel of internationally recognised experts for the 3rd Astellas Innovation Debate: i-Genes – What the DNA and Data Revolutions mean for our Health, taking place on Thursday 29th January 2015 at the Royal Institution of Great Britain.
Organised and funded by Astellas, a progressive pharmaceutical company that explores the frontiers of scientific discovery to translate new knowledge into innovative, reliable medicines, the Astellas Innovation Debates are a series of annual events that bring together some of the world’s most progressive thinkers to discuss the role of innovation in solving some of the greatest challenges of our time.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7424051-helena-kennedy-astellas-debate/
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
The Partnership for Drug-Free Kids, a national nonprofit dedicated to reducing substance abuse among adolescents, today launched a new multimedia campaign for teens that illustrates some of the pressures they face, including peer pressure to drink and use drugs, issues with body image and bullying, among others. The “Who Controls You” campaign breaks this month and was created pro-bono by advertising agency, Hill Holliday and award-winning, social media influencer, Maris Jones, as part of the Partnership’s Above the Influence (ATI) teen program.
“We are incredibly proud of this work. We struck gold when Hill Holliday collaborated with Adolescent Media and Maris Jones to bring this campaign to life,” said Chief Marketing Officer for the Partnership for Drug-Free Kids, Kristi Rowe. “Partnering with a young, talented social media influencer like Maris lent such a unique and authentic voice to this effort. Combining the extraordinary insight and passion of the Hill Holliday team with Maris’ distinct artistry brought an unexpected style to the campaign that makes this creative truly break through.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7103751-drug-free-partnership-who-controls-you/
Researchers at global public health organization NSF International, Harvard Medical School, the United States Department of Defense and the National Institute for Public Health and the Environment in the Netherlands (RIVM) recently identified four unapproved, DMAA-like stimulants in six over-the-counter weight-loss and pre-workout products currently available online. The research was published in the peer-reviewed journal Clinical Toxicology.
The potentially harmful compounds – including banned stimulants 1,3-DMAA and 1,3-DMBA as well as octodrine and a newly identified DMAA analog – were not listed as ingredients in the products and may have been disguised as “2-aminoisoheptane” or extract of Aconitum kusnezoffii. These stimulants may cause adverse cardiac events, hemorrhagic strokes or sudden death, especially if taken prior to strenuous exercise or combined with caffeine. Extreme heat and dehydration may also increase the health risks.
To view the multimedia release go to:
https://www.multivu.com/players/English/8216951-nsf-international-banned-stimulants-2-aminoisoheptane/
Do science and religion conflict? Is there disagreement between science and spirituality? It turns out there is no conflict. The apparent conflict is because, till now, the metaphors of ancient texts such as the Bible, Talmud, and ancient Yoga Literature, had not been rigorously studied and compared to cutting edge scientific discoveries. Some of these studies have been reviewed by scientists and published in three international peer-reviewed scientific journals. Sanjay's research on the new agreements between spirituality and science is the first ever to get published in such high-ranking journals.
By Sanjay C. Patel, Author of GOD IS REAL - The Stunning New Convergence of Science and Spirituality. Visit: http://www.SanjayCPatel.com
A ten-month clinical trial at Sentara Leigh Hospital in Norfolk, Virginia has determined that hard surfaces and linens infused with copper oxide compounds contributed to an 83% reduction in C-difficile and a 78% overall reduction in a host of multi-drug resistant organisms (MDROs) including C-diff, MRSA and VRE in a real-world clinical environment. These results occurred in a hospital with a robust protocol for managing infection risk certified by the health care accrediting body DNV-GL Healthcare.
The results of the trial were published in the peer-reviewed American Journal of Infection Control on Sept. 28, 2016 and will be presented at the annual conference of the Infectious Disease Society of America in New Orleans, Louisiana on October 27, 2016.
To view the multimedia release go to:
http://www.multivu.com/players/English/7955751-sentara-healthcare-infections-copper-clinical-trial/
Amid increasing reports of sexual assaults among college students, the Integrated Innovation Institute at Carnegie Mellon University is applying its distinctive innovation approach to accelerate marketable solutions to combat acquaintance/date rape. Two novel product prototypes, targeted to the college population and designed by graduate-student teams, employ mobile technology to galvanize bystander intervention and engender shared community responsibility.
To view the multimedia assets associated with this release, please click: http://www.multivu.com/players/English/7281051-carnegie-mellon-integrated-innovation-institute-students-innovate-against-rape/
https://www.cusd.money
cUSD is your digital money so people can live better lives. "A fast way to transfer money globally in secured digital transactions." Almost fee free transactions, a decentralized network that is peer to peer. cUSD Currency is for everyone!
